TY - JOUR
T1 - Trends in interorganizational transactions in personalized medicine development
AU - Makino, Tomohiro
AU - Sengoku, Shintaro
AU - Ishida, Shuichi
AU - Kodama, Kota
N1 - Funding Information:
We acknowledge the support from JSPS KAKENHI Grant Numbers JP23730336 and JP15H05183 . We also appreciate the open source and database developers used in this research. We would like to thank Editage ( www.editage.jp ) for English language editing.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2019/2
Y1 - 2019/2
N2 - Personalized medicine is an innovative concept that allows patients with a validated companion diagnosis (CoDx) to receive treatment using the most suitable drug. Currently, a major movement in the pharmaceutical industry involves the integrated use of multiple resources from external sources. To ascertain preferable interorganizational collaborations and their suitable exits, we compared the related transactions in personalized and nonpersonalized cancer drugs. We found that there were significantly more of some alliance deals in personalized medicine, and that market licenses, one of the exits, were well correlated with other alliances only in personalized medicine. Furthermore, four types of collaboration mode were identified, and more active collaborations with external partners were found to lead to more successful outcomes in personalized medicine development.
AB - Personalized medicine is an innovative concept that allows patients with a validated companion diagnosis (CoDx) to receive treatment using the most suitable drug. Currently, a major movement in the pharmaceutical industry involves the integrated use of multiple resources from external sources. To ascertain preferable interorganizational collaborations and their suitable exits, we compared the related transactions in personalized and nonpersonalized cancer drugs. We found that there were significantly more of some alliance deals in personalized medicine, and that market licenses, one of the exits, were well correlated with other alliances only in personalized medicine. Furthermore, four types of collaboration mode were identified, and more active collaborations with external partners were found to lead to more successful outcomes in personalized medicine development.
UR - http://www.scopus.com/inward/record.url?scp=85061978934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061978934&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2018.09.022
DO - 10.1016/j.drudis.2018.09.022
M3 - Short survey
C2 - 30339822
AN - SCOPUS:85061978934
SN - 1359-6446
VL - 24
SP - 364
EP - 370
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 2
ER -
